The purpose of this study is to assess the safety and efficacy of Gemcitabine/cisplatin combined with Adebrelimab and Mecapegfilgrastim in neoadjuvant treatment of potentially resectable Biliary Tract Neoplasms.
Male or female
Age ≥ 18 years，≤ 75 years
Patients with untreated resectable locally advanced biliary tract cancer (BTC) who are difficult to directly resecte surgically
Ability to provide written informed consent prior to participation in any study-related procedure
Diagnosis of mixed ampullary, hepatocellular, and cholangiocarcinoma
Known history of a serious allergy to any monoclonal antibody
Any active malignancy prior to the start of treatment
Active or history of autoimmune disease
The First Affiliated Hospital with Nanjing Medical University
Lead sponsor